Astrazeneca Pharma India Ltd
NSE:ASTRAZEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Astrazeneca Pharma India Ltd
Other Current Liabilities
Astrazeneca Pharma India Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Astrazeneca Pharma India Ltd
NSE:ASTRAZEN
|
Other Current Liabilities
₹2.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Other Current Liabilities
₹68.8B
|
CAGR 3-Years
16%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Other Current Liabilities
₹30.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
15%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Other Current Liabilities
₹118.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
19%
|
CAGR 10-Years
7%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Other Current Liabilities
₹30.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
20%
|
CAGR 10-Years
17%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Other Current Liabilities
₹11.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
2%
|
|
Astrazeneca Pharma India Ltd
Glance View
AstraZeneca Pharma India Ltd., a pivotal name in the Indian pharmaceutical landscape, is an integral arm of the global biopharmaceutical titan, AstraZeneca PLC headquartered in Cambridge, UK. The company has woven itself into the fabric of healthcare by consistently delivering novel medicines designed to combat a range of illnesses that include oncology, cardiovascular, renal, and metabolic diseases, as well as respiratory ailments. In India, AstraZeneca Pharma has carved out a reputation for not only introducing cutting-edge research and development capabilities but also adapting its global innovations to fit the unique demands of the local market. By leveraging a robust pipeline of therapeutic solutions, the company plays a crucial role in the intersection of healthcare and technology, aiming to improve patient outcomes through personalized medicine and bioscience-led innovations. The business model of AstraZeneca Pharma India is anchored in its commitment to research-driven innovation and strategic partnerships. Revenue streams are tightly interlinked with the company’s ability to successfully commercialize its extensive portfolio of patented medicines. AstraZeneca focuses on maintaining strong relationships with healthcare professionals and stakeholders, which are pivotal in driving prescriptions and ensuring the adoption of its novel therapies. Sales and distribution channels are fortified through collaborations with hospitals, pharmacies, and other healthcare providers, ensuring a broad reach across the country. The company continues to invest in its capabilities to educate and train medical professionals, thus enhancing its influence in the medical community and reinforcing its position as a market leader in providing life-saving medications.
See Also
What is Astrazeneca Pharma India Ltd's Other Current Liabilities?
Other Current Liabilities
2.2B
INR
Based on the financial report for Dec 31, 2025, Astrazeneca Pharma India Ltd's Other Current Liabilities amounts to 2.2B INR.
What is Astrazeneca Pharma India Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
4%
Over the last year, the Other Current Liabilities growth was 43%. The average annual Other Current Liabilities growth rates for Astrazeneca Pharma India Ltd have been 15% over the past three years , 13% over the past five years , and 4% over the past ten years .